USA

News

Guerbet To Showcase Innovative Diagnostic and Interventional Imaging Solutions at RSNA 2018

30.11.2018 18:52

New and Next-Level Management Products Available for Demonstration in Interactive Workstations   Congratulates Avner Meoded, MD, Johns Hopkins University, as recipient of the Guerbet/RSNA Research Scholar Grant

PRINCETON, N.J., November 26, 2018 – Guerbet LLC USA, the U.S. affiliate of the global specialist in contrast media products and comprehensive end-to-end solutions for medical imaging, will highlight new and next-level product offerings and partnerships in contrast media, injectors, disposables, digital solutions, and services at the 2018 annual meeting of the Radiological Society of North America (RSNA) in Chicago, Illinois.

At Guerbet’s booth 2558, interactive workstations will provide live demonstrations of novel clinical tools for diagnostic and interventional imaging, including:

• Contrast & Care®, a next-level contrast media injection management solution that enables imaging centers to collect, archive, examine and share data directly with Guerbet’s injectors to help radiologists with patient care, and;

• Imalogix, a new self-learning neural network that enables organizations to understand and benchmark best practices from the mass learnings in real time, across a network of providers to drive continuous improvement.

 

Guerbet will also highlight additional key milestones achieved this year, including:

• Product launches:

o SeQure® and DraKon™, two novel microcatheters for tumor and vascular aneurysm embolization procedures

o L-F Hydra Vision™ Digital Imaging System, a real-time digital X-ray imaging device in urological imaging

• Partnership:

o Joined forces with the Association for Medical Imaging Management (AHRA) “Defining Our Future” campaign, an initiative to support the education, development, and empowerment of new and future medical imaging professionals.

 

Guerbet’s macrocyclic ionic contrast agent Dotarem (gadoterate meglumine) remains the first and only macrocyclic & ionic GBCA molecule approved by the FDA, recently surpassing its 85 millionth dose worldwide. Celebrating the five-year anniversary of Dotarem’s U.S. launch in March 2013 (and its first pediatric and adult injections in July and September 2013 respectively), all on the heels of Dotarem’s “under age 2” pediatric approval last September, Guerbet continues to grow its success story and make positive impacts in the field.

Guerbet also proudly celebrates the granting of the Guerbet/RSNA Research Scholar Grant, by the RSNA Research & Education Foundation to Avener Meoded, MD, of Johns Hopkins University. The $150,000 two-year grant will help fund Dr. Meoded’s research using a comprehensive “omics” approach in the study of brain neuroplasticity in pediatric arterial ischemic stroke.

“Guerbet is proud to support a grantee seeking to make advances in pediatric brain neuroplasticity and enhance medical research,” said Massimo Carrara, Guerbet Vice President for North America. “It is an area in which we look forward to expanding as we continue to grow.”

To learn more, visit Guerbet at RSNA booth 2558, or www.guerbet-us.com/rsna2018.

Read Full Press Release and Important Information about Dotarem® (gadoterate meglumine) 

See Full Prescribing Information

 

About Guerbet

Guerbet is a pioneer in the contrast-agent field, with more than 90 years’ experience, and is a leader in medical imaging worldwide. It offers a comprehensive range of pharmaceutical products, medical devices and services for diagnostic and interventional imaging, to improve the diagnosis and treatment of patients. With 8% of revenue dedicated to R&D and more than 200 employees distributed amongst its four centers in France, Israel and the United States, Guerbet is a substantial investor in research and innovation. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €807 million in revenue in 2017. For more information about Guerbet, please visit www.guerbet.com

 

MEDIA RELATIONS

Guerbet US
Audrey Wallendal
US (609) 683-0700
awallendal(at)taftcommunications.com